Tourmaline Bio's 15-min chart shows KDJ Death Cross, Bearish Marubozu formation.

Based on the 15-minute chart for Tourmaline Bio, there has been a notable development in the stock's momentum. The KDJ Death Cross and Bearish Marubozu that occurred on September 26, 2025, at 14:15 indicate that the stock price is experiencing a shift towards a downward trajectory. This suggests that the momentum of the stock price is likely to continue on a bearish path, with sellers dominating the market. Therefore, there is a potential for further decreases in the stock price.

Tiziana Life Sciences (NASDAQ: TLSA) has announced plans to advance TZLS-501, its fully human anti-IL-6 receptor monoclonal antibody. This decision follows Novartis' recent acquisition of Tourmaline Bio for approximately $1.4 billion, indicating significant industry interest in IL-6 pathway therapeutics Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody^[1].

TZLS-501's dual mechanism of action targets both membrane-bound and soluble forms of IL-6R, blocking IL-6R signaling and reducing inflammatory cytokines. The company will pursue non-dilutive funding for TZLS-501's development while maintaining focus on its lead program, intranasal foralumab. The therapeutic shows potential for treating multiple conditions including rheumatoid arthritis, ARDS, pulmonary fibrosis, lupus, and various cancers.

The strategic move to advance TZLS-501 positions Tiziana to capitalize on the heightened industry interest in IL-6 targeting therapies. The company's decision to pursue non-dilutive funding for TZLS-501's development suggests a balanced approach aimed at expanding its therapeutic portfolio without diverting critical resources from ongoing clinical trials.

TZLS-501's unique ability to address both membrane-bound and soluble IL-6 signaling positions it as a potentially powerful therapy for acute and chronic inflammatory conditions. The recent acquisition by Novartis further validates the importance of IL-6 therapeutics, making this an opportune time for Tiziana to explore TZLS-501's development.

Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented, "Novartis’ recent acquisition of Tourmaline demonstrates how IL-6 therapy is increasingly valued in treating systemic inflammation and related diseases. While intranasal foralumab remains our lead program and primary focus, we are reviewing development opportunities for TZLS-501 as a complementary asset."

TZLS-501, a fully human mAb, was licensed from Novimmune, SA, in 2017. IL-6 is a cytokine that binds to its receptor subunit IL-6Rα on the cell membrane, and is a major determinant in priming of pathogenic T cells to produce an inflammatory response. The receptor IL-6Rα can be shed in soluble form, sIL6Rα, which binds to circulating IL-6 cytokine in the blood. The downstream signaling from this complex mediates pro-inflammatory effects underlying inflammatory diseases. TZLS-501 acts via a dual mechanism by inhibiting IL-6R signaling and depleting circulating levels of IL-6.

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. It is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Its innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery.